New drug combo shows promise for Hard-to-Treat brain cancer
NCT ID NCT04462328
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cannot receive standard high-dose chemotherapy. The goal is to find a safe dose and see if the combination can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Ohio State University Hospital
Columbus, Ohio, 43210, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune booster outsmart brain lymphoma?
- Can a daily pill keep brain lymphoma at bay after remission?
- Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?
- New antibody combo aims to treat brain lymphoma
- Could a cancer drug shrink recurrent brain tumors?
- New cocktail aims to shrink brain tumors